- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07933549
REstoration of Communication and LAnguage With Intracortical Microelectrodes (RECLAIM)
Early Feasibility Study of the Restoration of Communication and Language With Intracortical Microelectrodes (RECLAIM) System
The purpose of this study is to investigate the safety and feasibility of using distributed intracortical recordings from the language network to decode intended language output in individuals with severe communication impairment due to severe communication impairment resulting from amyotrophic lateral sclerosis (ALS), locked-in syndrome, and brain injury including from stroke.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Nitin Tandon, MD
- Número de teléfono: (713) 500-5456
- Correo electrónico: Nitin.Tandon@uth.tmc.edu
Copia de seguridad de contactos de estudio
- Nombre: Eliana Klier, PhD
- Número de teléfono: (713) 500-5442
- Correo electrónico: Eliana.Klier@uth.tmc.edu
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas Health Science Center at Houston
-
Investigador principal:
- Nitin Tandon, MD
-
Contacto:
- Nitin Tandon, MD
- Número de teléfono: (713) 500-5456
- Correo electrónico: Nitin.Tandon@uth.tmc.edu
-
Contacto:
- Eliana Klier, PhD
- Número de teléfono: (713) 500-5442
- Correo electrónico: Eliana.Klier@uth.tmc.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Clinical diagnosis of ALS, locked-in syndrome, or stroke
- ALS - ALS patients who in the opinion of the treating neurologist have at least 3 years of survival
- Locked-in Syndrome as a result of brain-stem stroke or traumatic brain-stem injury - patients who in the opinion of the treating neurologist have at least 3 years of survival
- Stroke (either ischemic or hemorrhagic) - for patients with prior stroke, the original cause of the stroke (e.g., arteriovenous malformation, carotid stenosis, atrial fibrillation, heart disease, hypertension) must have been addressed and the patient must not have had a recurrent stroke at least within the prior 12 months
-
ALS diagnosis, stroke, or Locked-in syndrome (LIS) etiology onset occurred at least one year prior to enrollment
-
Minimal communication ability as assessed by a speech-language pathologist
- unable to produce more than 10 total unique intelligible words when reading the Rainbow Passage and Grandfather Passage, and
- unable to write or type more than 10 unique words from a dictated list of 20 words.
-
Limited upper limb strength based on the Medical Research Council Scale for Muscle Strength
- ≤3/5 strength throughout both arms for those with non-progressive conditions (stroke or traumatic brain-stem injury)
- ≤4/5 strength throughout both arms for those with ALS
i. For patients with 4/5 strength, they must have a documented decline in speech or upper extremity function in the preceding 12 months.
-
Has a means of communication sufficient to enable understanding of research protocol and provide consent (e.g. eye blinks or eye movements, use of assistive technology). Thus patients are severely impaired with regards to naturalistic communication, but able to make decisions regarding their own care
-
Ability to understand and comply with study session instructions
-
Must live within a 90-minute drive of study site and willing to travel to study site up to three days per week for duration of the study
-
Has a stable psychosocial support system with caregiver capable of providing care during post-operative periods and monitoring participant throughout the study
-
Stable ventilator status - ventilator requirements have not changed over prior 6 months and ventilator status does not impose additional substantial risks to subject participation, including travel to the investigation site
Exclusion Criteria:
- Psychiatric conditions including current diagnosis of major psychiatric illness, significant cognitive impairment (based on a neuropsychological assessment by a clinical psychologist), suicidal ideation with intent/plan. [Columbia-Suicide Severity Rating Scale (C-SSRS) Categories 4-5)] or suicidal behavior within 12 months, or substance abuse/narcotic/alcohol dependence within 12 months.
- Neurological disorders including current diagnosis of epilepsy, abnormal pre-surgical neuroimaging precluding safe implant placement (per neurosurgical team), prior ipsilateral craniotomy, or hydrocephalus with or without ventricular shunt.
- Implanted electronic devices including pacemakers, cardiac defibrillators, spinal cord stimulators, vagal nerve stimulators, deep brain stimulators, or cochlear implants.
- Cardiovascular disorders including acute myocardial infarction (MI) or cardiac arrest within 6 months, significant cardiovascular impairment contraindicating surgery.
- Hematological disorders requiring chronic anticoagulation and medical contraindication to discontinuing anticoagulant medications perioperatively.
- Dermatological conditions causing excessive skin sloughing, poor wound healing, existing scalp lesions, or skin breakdown.
- Infectious/immunological conditions including active infections, unexplained fever, HIV infection, ongoing chronic infections, medical conditions predisposing to high infection risk, chronic steroid or immunosuppressive therapy, or active cancer within 1 year requiring chemotherapy.
- Medical contraindications including conditions contraindicating chronically implanted devices (osteomyelitis, diabetes, hepatic failure, autoimmune disease/disorders with associated altered immune responses) or other chronic unstable medical conditions interfering with participation.
- Surgical contraindications including medical contraindications to general anesthesia, craniotomy, or surgery; significant pulmonary, metabolic, or renal impairments making surgical procedure unsafe.
- Other exclusions including pregnancy (confirmed by blood test), nursing, inadequate contraception, correction vision worse than 20/100, limited English proficiency, or concurrent participation in device/drug trials.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: RECLAIM System
|
6 microelectrode grids will be implanted within the dominant hemisphere, placed across key speech and language cortical regions. The device will be kept implanted for up to 5 years and study sessions will be conducted 3-5 times per week |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Safety as assessed by the number and type of adverse events that occur
Periodo de tiempo: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety as assessed by the number of participants with device explanted
Periodo de tiempo: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Safety as assessed by the number of participants with Serious Adverse Events that result in death or permanently increased disability
Periodo de tiempo: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Effectiveness of the device as assessed by the Word error rate (WER)
Periodo de tiempo: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of device as assessed by the Phoneme error rate (PER)
Periodo de tiempo: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of the device as assessed by the Bilingual Evaluation Understudy (BLEU) Score
Periodo de tiempo: Every three months for the first two years post-implant
|
BLEU (Bilingual Evaluation Understudy) quantifies, on a range of 0-1, the overlap between the decoded text and the reference text based on matching n-grams. Higher BLEU scores indicate that the decoded output more closely matches the reference at the level of local word sequences. |
Every three months for the first two years post-implant
|
|
Effectiveness of the device as assessed by the Bidirectional Encoder Representations from Transformers (BERT) Score
Periodo de tiempo: Every three months for the first two years post-implant
|
BERT Score compares the semantic similarity (on a range of -1 to 1) between the decoded text sequence and the reference text using a pretrained language model (BERT). Higher scores indicated stronger semantic alignment. |
Every three months for the first two years post-implant
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Desordenes mentales
- Heridas y Lesiones
- Enfermedades Neuromusculares
- Enfermedades metabólicas
- Manifestaciones neuroconductuales
- Enfermedades neurodegenerativas
- Trastornos del neurodesarrollo
- Trauma craneoencefálico
- Trauma, Sistema Nervioso
- Enfermedades de la médula espinal
- Proteinopatías TDP-43
- Deficiencias de proteostasis
- Enfermedad de la neuronas motoras
- Parálisis
- Cuadriplejia
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Signos y síntomas
- Síndrome de enclaustramiento
- Carrera
- Lesiones Cerebrales
- La esclerosis lateral amiotrófica
- Desordenes comunicacionales
Otros números de identificación del estudio
- HSC-MS-26-0020
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .